Merck Gives Weak Q1 Outlook

The drug giant sees EPS of 95-98 cents, below analyst views for $1.01. But Merck

could report positive results on several drug candidates, said a UBS analyst, who kept a buy rating. The company formed a collaboration with Abbott Laboratories

to create a diagnostic test for specific DNA sequences to determine a patient's best course of therapy. Shares fell nearly 3%.